Exelixis EXEL Total debt
Total debt at other companies
Other financials
Where this comes from
Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $169.54M.
The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exelixis's total debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exelixis's total debt?
- Exelixis (EXEL) reported total debt of $169.54M in Q1 2026.
- How has Exelixis's total debt changed year-over-year?
- Exelixis's total debt decreased by 9.4% year-over-year, from $187.13M to $169.54M.
- What is the long-term trend for Exelixis's total debt?
- Over 5 years (2020 to 2025), Exelixis's total debt has grown at a 31.0% compound annual growth rate (CAGR), from $52.11M to $200.92M.
- What does total debt mean?
- The total amount of money a company owes to banks, bondholders, and other lenders.
- How do you interpret total debt?
- An increase in total debt suggests higher financial leverage and increased interest expense, which may heighten financial risk, while a decrease indicates deleveraging and improved balance sheet strength.
- How does total debt compare across companies?
- Biopharmaceutical companies often maintain lower debt levels compared to capital-intensive industries, though debt usage varies significantly based on the stage of the drug development pipeline and commercialization maturity.